TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07103668: An Open-label, Randomized, Comparative Phase III Study Including Patients With CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer.

Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07103668 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07103668 Rescue Dossier →